Effects of multiple sclerosis and medications on menopausal age. Issue 3 (March 2018)

• Record Type: Journal Article
• Authors: Türk Börü, Ülkü; Köseoğlu Toksoy, Cansu; Bölük, Cem; Bilgiç, Adnan; Taşdemir, Mustafa
• Is Part Of: Journal of international medical research. Volume 46:Issue 3(2018)
• Page Start: 1249
• Page End: 1253
• Publication Date: 2018-03
• Subjects: Multiple sclerosis -- disease-modifying drugs -- menopause -- methylprednisolone -- beta interferon -- Expanded Disability Status Scale (EDSS); Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060517746026
• Languages: English
• ISSNs: 0300-0605

Abstract

Objectives: We aimed to determine whether multiple sclerosis (MS) and methylprednisolone and disease-modifying drugs have an effect on menopausal age. Methods: A total of 86 patients and 98 healthy subjects were included in this study. The natural menopausal age of the patients and healthy subjects were compared. The cumulative dosages of methylprednisolone, beta interferons (IFNβs), and glatiramer acetate were calculated. The effects of the Expanded Disability Status Scale (EDSS), duration of the disease, and cumulative dosage of medications on menopausal age were evaluated. Results: The patients' mean menopausal age was 45.3 ± 4.8 years and healthy subjects' menopausal age was 46.8 ± 4.3 years, with no significant difference between the two groups. The cumulative dosage of methylprednisolone showed an effect on menopausal age. There was a significant inverse correlation between menopausal age and dosage of IFNβ-1b, while the disease duration and EDSS score showed no correlation with menopausal age. Conclusions: We conclude that menopausal age is not affected by MS. However, long-term methylprednisolone and IFNβ-1b treatments may change menopausal age in a dose-dependent manner.